Non-Malignant Hematology Certificate

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This continuing pharmacy education activity is intended for pharmacists who wish to develop their knowledge and skills in non-malignant hematology drug therapy and pharmacy practice.

Foundational Hematology
0204-0000-22-813-H01-P

• Describe the roles of pharmacists practicing in hematology.
• Identify laboratory tests relevant to hematology practice and the settings in which they may be utilized.
• Discuss regulations and national patient safety goals relevant to hematology pharmacy practice.
• Apply principles of hematology pharmacy practice to cases of drug-induced hematologic disorders. 

Bleeding Disorders: Pathophysiology
0204-0000-22-814-H01-P

• Describe the pathophysiology of hemophilia A and B with and without inhibitors, von Willebrand disease, and rare congenital factor deficiencies.
• Evaluate treatment options for hemophilia A and B with and without inhibitors, von Willebrand disease, and rare congenital and acquired factor deficiencies.
• Describe management considerations for pregnant patients with congenital bleeding disorders. 

Bleeding Disorders: Acute Care
0204-0000-22-815-H01-P

• Describe factor replacement goals and treatment strategies for patients with hemophilia A and B with and without inhibitors in acute care settings.
• Design a factor regimen for emergent bleeding in patients with hemophilia A and B with and without inhibitors, congenital von Willebrand disease, acquired bleeding disorders, and rare factor deficiencies.
• Design a factor regimen for peri-operative presentations for hemophilia A and B with and without inhibitors, congenital von Willebrand disease, acquired bleeding disorders, and rare factor deficiencies.
• Discuss formulary management strategies for non-malignant hematology medications.
• Outline the mission and components of a blood factor stewardship program.
• Identify strategies for optimizing factor use in the inpatient setting. 

Bleeding Disorders: Chronic Care
0204-0000-22-816-H01-P

• Apply differences among therapeutic options for prophylaxis in hemophilia A to therapy initiation.
• Select strategies to improve adherence to prophylaxis in pediatric patients.
• Summarize medication-related aspects of the management of menorrhagia in adolescents.
• Summarize medication-related aspects of the transition to adult bleeding disorder care.
• Design treatment plans for chronic management of hemophilia A and B, and von Willebrand disease.
• Evaluate current data about gene therapy for hemophilia A and B.
• Identify opportunities and strategies for engaging with home health services to support patients with bleeding disorders.
• Define hemophilia treatment centers and contract specialty pharmacy.
• Discuss contract pharmacy relationships and compliance strategies.  

Anemias - Red Blood Cell Production Disorders
0204-0000-22-817-H01-P

• Compare laboratory and clinical characteristics of anemia due to B12, folate, and iron deficiencies.
• Develop treatment plans for management of B12, folate, and iron deficiency anemias.
• Identify the pathophysiology of, and optimal treatment strategies for, hemolytic anemias and anemia of chronic disease.
• Develop a treatment plan for iron deficiency anemia during pregnancy.
• Discuss the use of erythropoiesis-stimulating agents for management of anemia associated with cancer.
• Recognize the need for bloodless medicine care.
• Apply best bloodless medicines practices to patient care.  

Hemoglobinopathies / Sickle Cell Syndromes
0204-0000-22-818-H01-P

• Review the epidemiology and pathophysiology of sickle cell syndromes.
• Identify sickle cell disease modifying agents and their roles in therapy.
• Design an individualized therapy plan to optimize sickle cell treatment.
• Apply appropriate acute and chronic supportive care measures for patients with sickle cell disease.
• Describe pathophysiology and appropriate management of thalassemia.
• Identify disease-specific considerations surrounding the use of hematopoietic cell transplantation and gene therapy in patients with sickle cell disease.
• Describe pediatric-specific considerations in the management of sickle cell disease from infancy to young adulthood. 

Platelet Disorders and Thrombotic Microangiopathies
0204-0000-22-819-H01-P

• Identify etiologies of thrombocytopenia.
• Describe the prevalence, pathophysiology, clinical presentation, and diagnosis of immune thrombocytopenia and thrombotic microangiopathies including typical and atypical hemolytic uremic syndrome (HUS), and thrombotic thrombocytopenic purpura (TTP).
• Analyze clinical practice guidelines for the management of immune thrombocytopenia and thrombotic microangiopathies including typical and atypical hemolytic uremic syndrome (HUS), and thrombotic thrombocytopenic purpura (TTP).
• Compare the efficacy and safety of current treatment options for immune thrombocytopenia and thrombotic microangiopathies including typical and atypical hemolytic uremic syndrome (HUS), and thrombotic thrombocytopenic purpura (TTP).
• Differentiate the management of immune thrombocytopenia in children from that of adults.
• Explain operational considerations for therapeutic selection and acquisition of complement inhibitors.

Anticoagulation Part 1
0204-0000-22-820-H01-P

• Describe the pathophysiology of coagulation.
• Identify mechanisms of action of anticoagulants.
• Recommend an appropriate dose of warfarin based on pharmacogenetic information.
• Describe approaches to clinical implementation of pharmacogenetics and emerging considerations for direct oral anticoagulants.
• Describe the pathophysiology of thrombosis in, and diagnosis of, antiphospholipid syndrome and heparin-induced thrombocytopenia.
• Design appropriate anticoagulation treatment plans for patients with antiphospholipid syndrome and heparin-induced thrombocytopenia.
• Describe the pathophysiology of cancer that leads to hypercoagulability.
• Identify characteristics of patients, diseases, and treatments that confer additional risks for hypercoagulability in patients with cancer.
• Select appropriate treatment for venous thromboembolism (VTE) in cancer patients utilizing available evidence and guideline recommendations specific to the cancer population.
• Explain the epidemiology, pathophysiology, and treatment of thrombosis in pregnancy. 

Anticoagulation Part 2
0204-0000-22-821-H01-P

• Summarize current evidence and recommendations regarding the use of select anticoagulants in extremes of weight or following gastrointestinal surgery.
• Analyze current evidence regarding the use of direct oral anticoagulants in renal impairment including end stage renal disease.
• Describe the etiologies, pathophysiology, and laboratory derangements of disseminated intravascular coagulation.
• Develop appropriate treatment strategies for patients with disseminated intravascular coagulation.
• Describe the epidemiology and pathophysiology of pediatric venous thromboembolism (VTE).
• Summarize clinical data and recommendations regarding the use of anticoagulants in the pediatric population.
• Identify the various types of mechanical circulatory support and describe the associated anticoagulation strategies for adult and pediatric populations.
• Identify the appropriate agents for anticoagulation reversal and the types of scenarios requiring anticoagulation reversal. 

Antiplatelets
0204-0000-22-822-H01-P

• Describe the mechanisms of action of antiplatelet therapies.
• Interpret and apply CYP2C19 genotyping results to guide selection of an appropriate P2Y12 inhibitor.
• Summarize the indications and adverse effects of antiplatelet medications. 

Myeloproliferative Neoplasms and Bone Marrow Failure Syndromes
0204-0000-22-823-H01-P

• Describe the clinical presentation and diagnosis of myeloproliferative neoplasms (polycythemia vera) and bone marrow failure disorders.
• Analyze clinical practice guidelines for myeloproliferative neoplasms (polycythemia vera) and bone marrow failure disorders.
• Choose appropriate treatment and supportive care for patients with myeloproliferative neoplasms (polycythemia vera) and aplastic anemia.
• Describe the clinical presentation and diagnosis of myeloproliferative neoplasms (essential thrombocytosis) and bone marrow failure disorders.
• Analyze clinical guidelines for myeloproliferative neoplasms (essential thrombocytosis) and bone marrow failure disorders.
• Choose appropriate treatment and supportive care for patients with myeloproliferative neoplasms (essential thrombocytosis) and aplastic anemia.
• Describe the clinical presentation and diagnosis of myeloproliferative neoplasms (myelofibrosis) and bone marrow failure disorders.
• Analyze clinical guidelines for myeloproliferative neoplasms (myelofibrosis) and bone marrow failure disorders.
• Choose appropriate treatment and supportive care for patients with myeloproliferative neoplasms (myelofibrosis) and aplastic anemia.
• Describe the clinical presentation and diagnosis of myeloproliferative neoplasms and bone marrow failure disorders (aplastic anemia).
• Analyze clinical practice guidelines for myeloproliferative neoplasms and bone marrow failure disorders (aplastic anemia).
• Choose appropriate treatment and supportive care for patients with myeloproliferative neoplasms and aplastic anemia.
• Identify best practices and opportunities to enhance the care of patients with myeloproliferative neoplasms and bone marrow failure disorders.

Rare Diseases in Hematology
0204-0000-22-824-H01-P

• Describe the prevalence, pathophysiology, clinical presentation, and diagnosis of select rare hematologic disorders (hemophagocytic lymphohistiocytosis).
• Select appropriate pharmacologic treatment for rare hematologic disorders (hemophagocytic lymphohistiocytosis).
• Analyze current guideline recommendations for the diagnosis and treatment of hemophagocytic lymphohistiocytosis.
• Summarize the roles of emapalumab and anakinra in the treatment of hemophagocytic lymphohistiocytosis.
• Describe the prevalence, clinical presentation, and diagnosis of rare hematologic disorders (porphyria).
• Select appropriate pharmacologic treatment for rare hematologic disorders (porphyria).
• Describe the prevalence, clinical presentation, and diagnosis of rare hematologic disorders (Langerhans cell histiocytosis).
• Select appropriate pharmacologic treatment for rare hematologic disorders (Langerhans cell histiocytosis).
• Analyze the role of tyrosine kinase inhibitors for the treatment of systemic mastocytosis, Langerhans cell histiocytosis, and hypereosinophilic syndrome.
• Describe the prevalence, clinical presentation, and diagnosis of rare hematologic disorders (systemic mastocytosis).
• Select appropriate pharmacologic treatment for rare hematologic disorders (systemic mastocytosis).
• Describe the prevalence, clinical presentation, and diagnosis of rare hematologic disorders (hypereosinophilic syndrome).
• Select appropriate pharmacologic treatment for rare hematologic disorders (hypereosinophilic syndrome).
• Describe the prevalence, clinical presentation, and diagnosis of rare hematologic disorders (hereditary hemorrhagic telangiactasia).
• Select appropriate pharmacologic treatment for rare hematologic disorders (hereditary hemorrhagic telangiactasia).
• Summarize the pathophysiology and optimal supplementation management of copper deficiency.

Review and Justification of Hematology Pharmacy Services
0204-0000-22-825-H01-P

• Develop a non-malignant hematology experience for pharmacy learners.
• Describe roles and responsibilities of inpatient non-malignant hematology clinical pharmacists.
• Discuss opportunities for pharmacist involvement in non-malignant hematology stewardship program development.
• Identify opportunities for pharmacist impact on the cost of care for hospitalized patients with non-malignant hematologic conditions.
• Evaluate opportunities for pharmacist involvement in outpatient non-malignant hematology clinical practice.
• Develop strategies for justifying non-malignant hematology pharmacy staff positions.

Lindsey Amerine, PharmD, MS, BCPS, FASHP
Director of Pharmacy
UNC Health
Associate Professor of Clinical Education
University of North Carolina Eshelman School of Pharmacy
Chapel Hill, North Carolina

Justin Arnall, PharmD, BCOP
Clinical Coordinator, Bleeding Disorders and Hematology
Atrium Health Specialty Pharmacy Service
Charlotte, North Carolina 

Amber Cipriani, PharmD, BCOP
Precision Medicine Pharmacy Coordinator
UNC Health
Clinical Assistant Professor
University of North Carolina Eshelman School of Pharmacy
Chapel Hill, North Carolina 

Kathryn Dane, PharmD, BCPS
Clinical Pharmacist, Benign Hematology and Cardiology
Co-Director, Hemostatic and Antithrombotic Stewardship Program
The Johns Hopkins Hospital
Baltimore, Maryland 

Catlin Goodfriend, PharmD
Clinical Pharmacist
Washington Center for Bleeding Disorders
Seattle, Washington 

Alexis Kuhn, PharmD, BCOP
Pediatric Oncology Pharmacist - Ambulatory Services
Mayo Clinic
Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Rochester, Minnesota 

John Lindsley, PharmD, BCPS, BCCCP
Clinical Pharmacy Specialist, Cardiology and Benign Hematology
Assistant Director, Hemostatic and Antithrombotic Stewardship
The Johns Hopkins Hospital
Baltimore, Maryland 

Donald Moore, PharmD, BCPS, BCOP, DPLA
Pharmacist Clinical Coordinator - Hematology/Oncology
Levine Cancer Institute, Atrium Health
Concord, North Carolina 

Surabhi Palkimas, PharmD
Benign Hematology Clinical Pharmacist
University of Colorado Hospital
Clinical Assistant Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado 

Leslie Ward, PharmD, BCPS, BCOP
Clinical Pharmacist, Benign Hematology
UVA Health
Charlottesville, Virginia 

Ashley Wester Huebschman, PharmD, BCPPS
Clinical Pharmacist Specialist - Pediatric Cardiology
C.S. Mott Children's Hospital
Michigan Medicine
Ann Arbor, Michigan

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships: 

• Justin Arnall: Novo Nordisk, speakers bureau
• Donald Moore: Oncopeptides, advisory board; AstraZeneca, advisory board
• Surabhi Palkimas: Novo Nordisk, advisor 

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As defined by the Standards of Integrity and Independence definition of ineligible company. All relevant financial relationships have been mitigated prior to the CPE activity.

This online activity consists of a combined total of 13 learning modules. Pharmacists are eligible to receive a total of 29.5 hours of continuing education credit by completing all 13 modules within this certificate.

Participants must participate in the entire activity, complete the evaluation and all required components to claim continuing pharmacy education credit online at ASHP Learning Center. Follow the prompts to claim credit and view your statement of credit within 60 days of completing the activity.

Important Note – ACPE 60 Day Deadline:

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, check your NABP eProfile account to validate that your credits were transferred successfully before the ACPE 60-day deadline.   After the 60 day deadline, ASHP will no longer be able to award credit for this activity.